AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
Summary
AstraZeneca is in talks to buy US drugmaker Bristol Myers Squibb in a deal that would create a nearly $400 billion pharmaceutical company. This merger would make the new company the fourth-largest drugmaker in the world by market value, but there is no certainty the deal will happen.Key Facts
- AstraZeneca is the UK’s biggest drugmaker, valued at nearly £196 billion before talks began.
- Bristol Myers Squibb (BMS) is a US-based company known for cancer treatments, worth $133 billion.
- The deal would create the world’s fourth-largest pharmaceutical company by market value.
- AstraZeneca’s shares dropped more than 7% in London after news of the talks.
- AstraZeneca is investing $50 billion in US research and manufacturing by 2030.
- BMS posted better-than-expected sales for the second quarter and raised its outlook for 2026.
- AstraZeneca’s CEO, Pascal Soriot, previously led the company through growth and avoided a takeover by Pfizer in 2014.
- There is no guarantee the deal will be completed despite ongoing discussions.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
